Clinical Trials on Mesothelioma

Total 527 results

ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma

Mesothelioma | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma Malignant | Mesothelioma; Lung | Mesothelioma; Liver | Mesothelioma; Omentum

United States
Åslaug Helland
Bristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASA

Active, not recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; Lung

Norway, Denmark, Sweden, Spain, Australia
Memorial Sloan Kettering Cancer Center
Gilead Sciences

Recruiting

A Study of Sacituzumab Govitecan in People With Mesothelioma

Mesothelioma | Mesotheliomas Pleural | Mesothelioma; Pleura

United States
University Hospital, Lille
INSERM U1189 ONCOTHAI

Recruiting

The IMmunotherapy Pleural 5-ALA PDT (IMPALA)

Malignant Pleural Mesothelioma | Mesotheliomas Pleural

France
Istituto Oncologico Veneto IRCCS

Recruiting

Immune Microenvironment and Gene Expression Profiling in Mesothelioma (Imaging-Meso)

Mesothelioma | Mesotheliomas Pleural | Mesothelioma; Lung

Italy
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Ain Shams University

Completed

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) (VITMPM)

Malignant Pleural Mesotheliomas

Egypt
Eli Lilly and Company

Completed

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Malignant Pleural Mesotherioma

Japan
Intergroupe Francophone de Cancerologie Thoracique
Summit Therapeutics

Not yet recruiting

Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS)

Pleural Mesotheliomas

France
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)

Mesotheliomas Pleural

Italy
Ankara University
Ankara Yildirim Beyazıt University; Liv Hospital Ankara; Social Sciences University...

Recruiting

Ga-68 FAPI PET Before Immunotherapy (FAPBI)

Mesotheliomas Pleural

Turkey
Erasmus Medical Center

Recruiting

dENdritic Cell Therapy Combined With SURgEry in Mesothelioma (ENSURE)

Mesotheliomas Pleural

Netherlands
Abramson Cancer Center at Penn Medicine

Recruiting

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Mesotheliomas Pleural

United States
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)

Mesotheliomas Pleural

Netherlands
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Recurrent Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Withdrawn

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Malignant Pleural Mesotheliomas (Mpm) | Malignant Pleural Effusions (Mpe) | Epithelial Tumors, Malignant | Pleural Effusions, Malignant | Mesothelin (Msln)

United States
National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Sarcomatoid Mesothelioma | Recurrent Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
NRG Oncology
National Cancer Institute (NCI)

Terminated

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...

United States, Canada
National Cancer Institute (NCI)

Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant Mesothelioma

United States
Maisonneuve-Rosemont Hospital

Completed

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Peritoneal Mesotheliomas

Canada
National Cancer Institute (NCI)

Terminated

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Lung Cancer | Carcinoma, Esophageal | Malignant Pleural Mesotheliomas

United States
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
National Cancer Institute (NCI)

Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Malignant Pleural Mesotheliomas NOS | Esophageal Cancers NOS | Lung Cancer NOS | Thoracic Cancers | Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura

United States
National Cancer Institute (NCI)

Terminated

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

Esophageal Cancer | Thymoma | Lung Cancer | Thoracic Sarcomas | Mesolthelioma

United States
National Cancer Institute (NCI)

Terminated

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

Primary Peritoneal Cavity Cancer | Malignant Ascites | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Canada
National Cancer Institute (NCI)

Active, not recruiting

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant Mesothelioma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Mesothelioma | Mesothelioma, Malignant | Malignant Mesothelioma | Peritoneal Mesothelioma | Malignant Peritoneal Mesothelioma

United States
Health Pharma Professional Research

Withdrawn

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, Unresectable

Mexico
TCR2 Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Cholangiocarcinoma | Non Small Cell Lung Cancer Metastatic | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma; Pleura | Cholangiocarcinoma Recurrent | High Grade Ovarian Serous Adenocarcinoma

United States, Canada
Hospices Civils de Lyon

Recruiting

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

Peritoneal Malignant Mesothelioma

Belgium, Portugal, France, Germany, India, Norway
Fundación GECP

Completed

Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)

Mesothelioma; Lung

Spain
Italian Network for Tumor Biotherapy Foundation
AstraZeneca

Unknown

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Peritoneal Mesothelioma | Pleural Mesothelioma

Italy
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma | Pleural Mesothelioma

United States
University of Chicago

Terminated

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Pleural Mesothelioma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Pleural Malignant Mesothelioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Pleural Malignant Mesothelioma

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Malignant Mesothelioma (MPM)

United States
National Cancer Institute (NCI)

Completed

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Peritoneal Mesothelioma | Pleural Mesothelioma

United States

Clinical Trials on Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations